[ 1 ] Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68(6):394–424. link1

[ 2 ] Cao W, Chen H, Yu YW, Li N, Chen W. Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020. Chin Med J 2021;134(7):783–91. link1

[ 3 ] Feng RM, Zong YN, Cao SM, Xu RH. Current cancer situation in China: good or bad news from the 2018 Global Cancer Statistics? Cancer Commun 2019;39 (1):22. link1

[ 4 ] Schwab I, Nimmerjahn F. Intravenous immunoglobulin therapy: how does IgG modulate the immune system? Nat Rev Immunol 2013;13(3):176–89. link1

[ 5 ] Wang J, Huang C, Zhou J, Zhao K, Li Y. Causal link between immunoglobulin G glycosylation and cancer: a potential glycobiomarker for early tumor detection. Cell Immunol 2021;361:104282. link1

[ 6 ] Kljakovic´ -Gašpic´ Batinjan M, Petrovic´ T, Vucˇkovic´ F, Hadzˇibegovic´ I, Radovani B, Jurin I, et al. Differences in immunoglobulin G glycosylation between influenza and COVID-19 patients. Engineering. In press.

[ 7 ] Shih HC, Chang MC, Chen CH, Tsai IL, Wang SY, Kuo YP, et al. High accuracy differentiating autoimmune pancreatitis from pancreatic ductal adenocarcinoma by immunoglobulin G glycosylation. Clin Proteomics 2019;16:1. link1

[ 8 ] Kodar K, Stadlmann J, Klaamas K, Sergeyev B, Kurtenkov O. Immunoglobulin G Fc N-glycan profiling in patients with gastric cancer by LC-ESI-MS: relation to tumor progression and survival. Glycoconj J 2012;29(1):57–66. link1

[ 9 ] Pinho SS, Reis CA. Glycosylation in cancer: mechanisms and clinical implications. Nat Rev Cancer 2015;15(9):540–55. link1

[10] Duffy MJ, van Dalen A, Haglund C, Hansson L, Holinski-Feder E, Klapdor R, et al. Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use. Eur J Cancer 2007;43(9):1348–60. link1

[11] Scott DW, Vallejo MO, Patel RP. Heterogenic endothelial responses to inflammation: role for differential N-glycosylation and vascular bed of origin. J Am Heart Assoc 2013;2(4):e000263. link1

[12] Kaneko Y, Nimmerjahn F, Ravetch JV. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 2006;313 (5787):670–3. link1

[13] Huffman JE, Pucˇic´ -Bakovic´ M, Klaric´ L, Hennig R, Selman MH, Vucˇkovic´ F, et al. Comparative performance of four methods for high-throughput glycosylation analysis of immunoglobulin G in genetic and epidemiological research. Mol Cell Proteomics 2014;13(6):1598–610. link1

[14] Ha S, Ou Y, Vlasak J, Li Y,Wang S, Vo K, et al. Isolation and characterization of IgG1 with asymmetrical Fc glycosylation. Glycobiology 2011;21(8):1087–96. link1

[15] Reily C, Stewart TJ, Renfrow MB, Novak J. Glycosylation in health and disease. Nat Rev Nephrol 2019;15(6):346–66. link1

[16] Gornik O, Wagner J, Pucic´ M, Knezevic´ A, Redzic I, Lauc G. Stability of N-glycan profiles in human plasma. Glycobiology 2009;19(12):1547–53. link1

[17] Ren S, Zhang Z, Xu C, Guo L, Lu R, Sun Y, et al. Distribution of IgG galactosylation as a promising biomarker for cancer screening in multiple cancer types. Cell Res 2016;26(8):963–96. link1

[18] Yi C, Weng H, Zhou F, Fang M, Ji J, Cheng C, et al. Elevated core-fucosylated IgG is a new marker for hepatitis B virus-related hepatocellular carcinoma. OncoImmunology 2015;4(12):e1011503. link1

[19] Qian Y, Wang Y, Zhang X, Zhou L, Zhang Z, Xu J, et al. Quantitative analysis of serum IgG galactosylation assists differential diagnosis of ovarian cancer. J Proteome Res 2013;12(9):4046–55. link1

[20] Vucˇkovic´ F, Theodoratou E, Thaçi K, Timofeeva M, Vojta A, Štambuk J, et al. IgG glycome in colorectal cancer. Clin Cancer Res 2016;22(12):3078–86. link1

[21] Fléjou JF. WHO Classification of digestive tumors: the fourth edition. Ann Pathol 2011;31(Suppl 5):S27–31. link1

[22] Serdarevic N. The comparison between different immunoassays for serum carbohydrate antigen (CA19–9) concentration measurement. Acta Inform Med 2018;26(4):235–9. link1

[23] Tie J, Cohen JD, Wang Y, Christie M, Simons K, Lee M, et al. Circulating tumor DNA analyses as markers of recurrence risk and benefit of adjuvant therapy for stage III colon cancer. JAMA Oncol 2019;5(12):1710–7. link1

[24] Jeschke MG, Kulp GA, Kraft R, Finnerty CC, Mlcak R, Lee JO, et al. Intensive insulin therapy in severely burned pediatric patients: a prospective randomized trial. Am J Respir Crit Care Med 2010;182(3):351–9. link1

[25] Hou H, Xu X, Sun F, Zhang X, Dong H, Wang L, et al. Hyperuricemia is associated with immunoglobulin G N-glycosylation: a community-based study of glycan biomarkers. OMICS 2019;23(12):660–7. link1

[26] Pucic´ M, Knezevic´ A, Vidic J, Adamczyk B, Novokmet M, Polasek O, et al. High throughput isolation and glycosylation analysis of IgG-variability and heritability of the IgG glycome in three isolated human populations. Mol Cell Proteomics 2011;10(10):M111.010090. link1

[27] Liu D, Xu X, Li Y, Zhang J, Zhang X, Li Q, et al. Immunoglobulin G N-glycan analysis by ultra-performance liquid chromatography. J Vis Exp 2020;155: e60104. link1

[28] Hou H, Yang H, Liu P, Huang C, Wang M, Li Y, et al. Profile of immunoglobulin G N-glycome in COVID-19 patients: a case-control study. Front Immunol 2021;12:748566. link1

[29] Liu D, Zhao Z, Wang A, Ge S, Wang H, Zhang X, et al. Ischemic stroke is associated with the pro-inflammatory potential of N-glycosylated immunoglobulin G. J Neuroinflammation 2018;15:123. link1

[30] Liu D, Li Q, Dong J, Li D, Xu X, Xing W, et al. The association between normal BMI with central adiposity and proinflammatory potential immunoglobulin G N-glycosylation. Diabetes Metab Syndr Obes 2019;12:2373–85. link1

[31] Huang G, Jin Q, Tian X, Mao Y. Development and validation of a carotid atherosclerosis risk prediction model based on a Chinese population. Front Cardiovasc Med 2022;9:946063. link1

[32] Wang W. Glycomedicine: the current state of the art. Engineering 2022. In press. link1

[33] Lauc G, Pezer M, Rudan I, Campbell H. Mechanisms of disease: the human Nglycome. Biochim Biophys Acta 2016;1860(8):1574–82. link1

[34] Šimurina M, de Haan N, Vucˇkovic´ F, Kennedy NA, Štambuk J, Falck D, et al. Glycosylation of immunoglobulin G associates with clinical features of inflammatory bowel diseases. Gastroenterology 2018;154(5):1320. link1

[35] Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature 2008;454(7203):436–44. link1

[36] Coussens LM, Werb Z. Inflammation and cancer. Nature 2002;420(6917):860–87. link1

[37] Elinav E, Nowarski R, Thaiss CA, Hu B, Jin C, Flavell RA. Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms. Nat Rev Cancer 2013;13(11):759–71. link1

[38] Berkovic´ M, Cacev T, Zjacic´ -Rotkvic´ V, Kapitanovic´ S. TNF-a promoter single nucleotide polymorphisms in gastroenteropancreatic neuroendocrine tumors. Neuroendocrinology 2006;84(5):346–52. link1

[39] Pavel ME, Hassler G, Baum U, Hahn EG, Lohmann T, Schuppan D. Circulating levels of angiogenic cytokines can predict tumour progression and prognosis in neuroendocrine carcinomas. Clin Endocrinol 2005;62(4):434–43. link1

[40] Tebbutt NC, Giraud AS, Inglese M, Jenkins B, Waring P, Clay FJ, et al. Reciprocal regulation of gastrointestinal homeostasis by SHP2 and STATmediated trefoil gene activation in gp130 mutant mice. Nat Med 2002;8 (10):1089–97. link1

[41] Böhm S, Schwab I, Lux A, Nimmerjahn F. The role of sialic acid as a modulator of the anti-inflammatory activity of IgG. Semin Immunopathol 2012;34 (3):443–53. link1

[42] Menni C, Gudelj I, Macdonald-Dunlop E, Mangino M, Zierer J, Bešic´ E, et al. Glycosylation profile of immunoglobulin G is cross-sectionally associated with cardiovascular disease risk score and subclinical atherosclerosis in two independent cohorts. Circ Res 2018;122(11):1555–64. link1

[43] Pagan JD, Kitaoka M, Anthony RM. Engineered sialylation of pathogenic antibodies in vivo attenuates autoimmune disease. Cell 2018;172(3):564. link1

[44] Tramentozzi E, Ruli E, Angriman I, Bardini R, Campora M, Guzzardo V, et al. Grp94 in complexes with IgG is a soluble diagnostic marker of gastrointestinal tumors and displays immune-stimulating activity on peripheral blood immune cells. Oncotarget 2016;7(45):72923–40. link1

[45] Dall’Olio F, Vanhooren V, Chen CC, Slagboom PE, Wuhrer M, Franceschi C. Nglycomic biomarkers of biological aging and longevity: a link with inflammaging. Ageing Res Rev 2013;12(2):685–98. link1

[46] Zhang X, Yuan H, Lyu J, Meng X, Tian Q, Li Y, et al. Association of dementia with immunoglobulin G N-glycans in a Chinese Han population. NPJ Aging Mech Dis 2021;7(1):3. link1

[47] Zou G, Ochiai H, Huang W, Yang Q, Li C, Wang X. Chemoenzymatic synthesis and Fcc receptor binding of homogeneous glycoforms of antibody Fc domain. Presence of a bisecting sugar moiety enhances the affinity of Fc to FccIIIa receptor. J Am Chem Soc 2011;133(46):18975–91. link1

[48] Russell AC, Šimurina M, Garcia MT, Novokmet M, Wang Y, Rudan I, et al. The Nglycosylation of immunoglobulin G as a novel biomarker of Parkinson’s disease. Glycobiology 2017;27(5):501–10. link1

[49] Ackerman ME, Crispin M, Yu X, Baruah K, Boesch AW, Harvey DJ, et al. Natural variation in Fc glycosylation of HIV-specific antibodies impacts antiviral activity. J Clin Invest 2013;123(5):2183–92. link1

[50] Wu Z, Pan H, Liu D, Zhou D, Tao L, Zhang J, et al. Association of IgG glycosylation and esophageal precancerosis beyond inflammation. Cancer Prev Res 2021;14(3):347–54. link1

[51] Theodoratou E, Thaçi K, Agakov F, Timofeeva MN, Štambuk J, Pucˇic´ -Bakovic´ M, et al. Glycosylation of plasma IgG in colorectal cancer prognosis. Sci Rep 2016;6:28098. link1

[52] Karsten CM, Pandey MK, Figge J, Kilchenstein R, Taylor PR, Rosas M, et al. Antiinflammatory activity of IgG1 mediated by Fc galactosylation and association of FccRIIB and dectin-1. Nat Med 2012;18(9):1401–6. link1

[53] Gornik O, Pavic´ T, Lauc G. Alternative glycosylation modulates function of IgG and other proteins—implications on evolution and disease. Biochim Biophys Acta 2012;1820(9):1318–26. link1

[54] Zhang D, Chen B, Wang Y, Xia P, He C, Liu Y, et al. Disease-specific IgG Fc Nglycosylation as personalized biomarkers to differentiate gastric cancer from benign gastric diseases. Sci Rep 2016;6:25957. link1

[55] Ding P, Xu Y, Li L, Lv X, Li L, Chen J, et al. Intracellular complement C5a/C5aR1 stabilizes b-catenin to promote colorectal tumorigenesis. Cell Rep 2022;39 (9):110851. link1

[56] Liu S, Huang Z, Zhang Q, Fu Y, Cheng L, Liu B, et al. Profiling of isomer-specific IgG N-glycosylation in cohort of Chinese colorectal cancer patients. Biochim Biophys Acta 2020;1864(3):129510. link1

[57] Zhong A, Qin R, Qin W, Han J, Gu Y, Zhou L, et al. Diagnostic significance of serum IgG galactosylation in CA19-9-negative pancreatic carcinoma patients. Front Oncol 2019;9:114. link1

[58] Qin R, Yang Y, Chen H, Qin W, Han J, Gu Y, et al. Prediction of neoadjuvant chemotherapeutic efficacy in patients with locally advanced gastric cancer by serum IgG glycomics profiling. Clin Proteomics 2020;17(1):4. link1

[59] Collins ES, Galligan MC, Saldova R, Adamczyk B, Abrahams JL, Campbell MP, et al. Glycosylation status of serum in inflammatory arthritis in response to anti-TNF treatment. Rheumatology 2013;52(9):1572–82. link1

[60] Croce A, Firuzi O, Altieri F, Eufemi M, Agostino R, Priori R, et al. Effect of infliximab on the glycosylation of IgG of patients with rheumatoid arthritis. J Clin Lab Anal 2007;21(5):303–14. link1

[61] Dekkers G, Treffers L, Plomp R, Bentlage AEH, de Boer M, Koeleman CAM, et al. Decoding the human immunoglobulin G-glycan repertoire reveals a spectrum of Fc-receptor- and complement-mediated-effector activities. Front Immunol 2017;8:877. link1

[62] Martin TC, Šimurina M, Za˛bczyn´ ska M, Martinic Kavur M, Rydlewska M, Pezer M, et al. Decreased immunoglobulin G core fucosylation, a player in antibodydependent cell-mediated cytotoxicity, is associated with autoimmune thyroid diseases. Mol Cell Proteomics 2020;19(5):774–92. link1

[63] Lauc G, Huffman JE, Pucˇic´ M, Zgaga L, Adamczyk B, Muzˇinic´ A, et al. Loci associated with N-glycosylation of human immunoglobulin G show pleiotropy with autoimmune diseases and haematological cancers. PLoS Genet 2013;9(1): e1003225. link1

[64] Chakraborty S, Gonzalez J, Edwards K, Mallajosyula V, Buzzanco AS, Sherwood R, et al. Proinflammatory IgG Fc structures in patients with severe COVID-19. Nat Immunol 2021;22(1):67–73. link1

[65] Chang CC, Cheng JJ, Lee IJ, Lu MK. Purification, structural elucidation, and antiinflammatory activity of xylosyl galactofucan from Armillaria mellea. Int J Biol Macromol 2018;114:584–91. link1

[66] Man SM. Inflammasomes in the gastrointestinal tract: infection, cancer and gut microbiota homeostasis. Nat Rev Gastroenterol Hepatol 2018;15 (12):721–37. link1

[67] Donlon NE, Davern M, O’Connell F, Sheppard A, Heeran A, Bhardwaj A, et al. Impact of radiotherapy on the immune landscape in oesophageal adenocarcinoma. World J Gastroenterol 2022;28(21):2302–19. link1

[68] Valenzuela P, Oaxaca D, Di Desidero T, Parra K, Rodriguez G, Manciu M, et al. Pharmacodynamic biomarkers in metronomic chemotherapy: multiplex cytokine measurements in gastrointestinal cancer patients. Clin Exp Med 2021;21(1):149–59. link1

[69] Irvine EB, Alter G. Understanding the role of antibody glycosylation through the lens of severe viral and bacterial diseases. Glycobiology 2020;30 (4):241–53. link1

[70] Fuster MM, Esko JD. The sweet and sour of cancer: glycans as novel therapeutic targets. Nat Rev Cancer 2005;5(7):526–42. link1

[71] Wang J, Balog CIA, Stavenhagen K, Koeleman CAM, Scherer HU, Selman MHJ, et al. Fc-glycosylation of IgG1 is modulated by B-cell stimuli. Mol Cell Proteomics 2011;10(5):M110.004655. link1

[72] Wang H, Li X, Wang X, Liu D, Zhang X, Cao W, et al. Next-generation (glycomic) biomarkers for cardiometabolic health: a community-based study of immunoglobulin G N-glycans in a Chinese Han population. OMICS 2019;23 (12):649–59. link1

[73] Dos Santos JM, Joiakim A, Kaplan DJ, Putt DA, Bakovic GP, Servoss SL, et al. Levels of plasma glycan-binding auto-IgG biomarkers improve the accuracy of prostate cancer diagnosis. Mol Cell Biochem 2021;476(1):13–22. link1

[74] Pan J, Yu L, Wu Q, Lin X, Liu S, Hu S, et al. Integration of IgA and IgG autoantigens improves performance of biomarker panels for early diagnosis of lung cancer. Mol Cell Proteomics 2020;19(3):490–500. link1

[75] Sheng Z, Liu Y, Qin C, Liu Z, Yuan Y, Yin H, et al. Involvement of cancer-derived IgG in the proliferation, migration and invasion of bladder cancer cells. Oncol Lett 2016;12(6):5113–21. link1